Innovate Research

🚀 Join Innovate Research at 𝗖𝗣𝗛𝗜 𝗣𝗠𝗘𝗖 𝗜𝗻𝗱𝗶𝗮 𝟮𝟬𝟮𝟰! 🚀 We’re thrilled to be showcasing our expertise at CPHI PMEC India and invite you to meet our team to discuss how we can support your clinical trial needs. As a regulatory-compliant, full-service CRO, we offer a comprehensive range of solutions: 🌍 𝗘𝗻𝗱-𝘁𝗼-𝗘𝗻𝗱 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀 From Phase I to Phase IV, including RWE, PMOS, vaccines, nutraceuticals, herbal, dermatology, cosmetics, medical devices, and more. 📜 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗶𝗻𝗴 & 𝗔𝗽𝗽𝗿𝗼𝘃𝗮𝗹𝘀 Guiding you through the regulatory landscape to ensure compliance and smooth approvals. 📊 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗗𝗮𝘁𝗮 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 With in-house solutions like ClinSoft and IWRS to streamline your trial processes. 🗓 𝗠𝗲𝗲𝘁 𝗨𝘀 𝗮𝘁 𝗖𝗣𝗛𝗜 𝗜𝗻𝗱𝗶𝗮 - 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟮𝟲-𝟮𝟴, 𝟮𝟬𝟮𝟰 Let’s connect and explore how we can collaborate to drive your projects forward. 💬 𝗦𝗰𝗵𝗲𝗱𝘂𝗹𝗲 𝗮 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝗧𝗼𝗱𝗮𝘆 Reach out to us at: BD@innovate-research.com and let’s discuss how we can make your next clinical trial a success! Looking forward to connecting with industry leaders and professionals! #innovateresearch #clinicaltrials #pharmaceuticals #research #PharmaExpo #Exposition #Pharmaceuticals #Nutraceuticals #CPHI #CPHIIndia #DataManagement #regulatoryservices #cphi #India #pharma #CRO #CDM #ClinSoft #IWRS #PageOne

🚨 𝗚𝗛𝗜𝗧 𝗙𝘂𝗻𝗱 𝗖𝗼𝗺𝗺𝗶𝘁𝘀 $𝟰 𝗠𝗶𝗹𝗹𝗶𝗼𝗻 𝘁𝗼 𝗙𝘂𝗻𝗱 𝗙𝗼𝘂𝗿 𝗣𝗿𝗼𝗷𝗲𝗰𝘁𝘀 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗮𝗻𝗱 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗡𝗧𝗗𝘀 𝗮𝗻𝗱 𝗠𝗮𝗹𝗮𝗿𝗶𝗮 🌍💉 The 𝗚𝗹𝗼𝗯𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 (𝗚𝗛𝗜𝗧) Fund has announced an exciting investment of 𝗝𝗣𝗬 𝟱𝟳𝟴 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 (USD 4.0 million) to support four groundbreaking projects aimed at developing 𝗻𝗲𝘄 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 and 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 for some of the world’s most neglected diseases, including 𝘁𝗿𝗮𝗰𝗵𝗼𝗺𝗮, 𝗺𝗮𝗹𝗮𝗿𝗶𝗮, and 𝗖𝗵𝗮𝗴𝗮𝘀 disease. Here’s what you need to know: 𝟭. 𝗡𝗲𝘄 𝗛𝗼𝗽𝗲 𝗳𝗼𝗿 𝗧𝗿𝗮𝗰𝗵𝗼𝗺𝗮: The GHIT Fund is investing JPY 280 million (USD 2.0 million) in a project to create a Rapid Diagnostic Test (RDT) for trachoma, a leading cause of blindness. This test will help doctors identify and treat the disease early, potentially saving the sight of over 100 million people at risk. This is the GHIT Fund’s first investment targeting trachoma. 𝟮. 𝗪𝗵𝘆 𝗧𝗿𝗮𝗰𝗵𝗼𝗺𝗮 𝗠𝗮𝘁𝘁𝗲𝗿𝘀: Trachoma is still a major health issue in 𝟯𝟵 𝗰𝗼𝘂𝗻𝘁𝗿𝗶𝗲𝘀, affecting millions of people and it’s spread through poor hygiene and contact with infected flies. The 𝗪𝗛𝗢 aims to eliminate trachoma as a public health problem by 𝟮𝟬𝟯𝟬, and early diagnosis is key to reaching that goal. 𝟯. 𝗙𝗶𝗴𝗵𝘁𝗶𝗻𝗴 𝗠𝗮𝗹𝗮𝗿𝗶𝗮 & 𝗖𝗵𝗮𝗴𝗮𝘀: The GHIT Fund is also supporting: • 𝗝𝗣𝗬 𝟭𝟱𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 (USD 1.0 million) for a new malaria drug project with Nagasaki University, Shionogi, and Medicines for Malaria Venture (MMV). • 𝗝𝗣𝗬 𝟳𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 (USD 0.49 million) to develop a diagnostic test for Chagas disease, with Nagasaki University and ISGlobal. • 𝗝𝗣𝗬 𝟳𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 (USD 0.48 million) to advance malaria drug discovery with The University of Tokyo, MMV, Oxford University, and University of Dundee. 𝟰. 𝗚𝗛𝗜𝗧 𝗙𝘂𝗻𝗱’𝘀 𝗜𝗺𝗽𝗮𝗰𝘁: Since its launch, the GHIT Fund has invested 𝗨𝗦𝗗 𝟮𝟯𝟲 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 in 𝟯𝟯 projects across the globe, working to create 𝗻𝗲𝘄 𝗱𝗿𝘂𝗴𝘀, 𝘃𝗮𝗰𝗰𝗶𝗻𝗲𝘀, and 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝘁𝗼𝗼𝗹𝘀 for diseases that affect the world’s most vulnerable populations. 👉 These projects represent a major step forward in the fight against diseases that often go unnoticed. Follow Innovate Research to stay updated. #GlobalHealth #innovateresearch #CRO #clinicaltrials #NTDs #Malaria #Trachoma #ChagasDisease #HealthcareInnovation #Pharma #GHITFund #Diagnostics #HealthForAll #MedicalResearch #PublicHealth #GlobalHealthEquity #R&D #HealthImpact #PublicPrivatePartnership

𝗪𝗛𝗢 𝘀𝘁𝘂𝗱𝘆 𝗹𝗶𝘀𝘁𝘀 𝘁𝗼𝗽 𝗲𝗻𝗱𝗲𝗺𝗶𝗰 𝗽𝗮𝘁𝗵𝗼𝗴𝗲𝗻𝘀 𝗳𝗼𝗿 𝘄𝗵𝗶𝗰𝗵 𝗻𝗲𝘄 𝘃𝗮𝗰𝗰𝗶𝗻𝗲𝘀 𝗮𝗿𝗲 𝘂𝗿𝗴𝗲𝗻𝘁𝗹𝘆 𝗻𝗲𝗲𝗱𝗲𝗱 A new study from the 𝗪𝗼𝗿𝗹𝗱 𝗛𝗲𝗮𝗹𝘁𝗵 𝗢𝗿𝗴𝗮𝗻𝗶𝘇𝗮𝘁𝗶𝗼𝗻 (𝗪𝗛𝗢) published in 𝘦𝘉𝘪𝘰𝘔𝘦𝘥𝘪𝘤𝘪𝘯𝘦 identifies 𝟭𝟳 𝗲𝗻𝗱𝗲𝗺𝗶𝗰 𝗽𝗮𝘁𝗵𝗼𝗴𝗲𝗻𝘀 as high-priority targets for new vaccine development. This global analysis considers the disease burden, risk of antimicrobial resistance, and the socioeconomic impact on communities, especially in low- and middle-income countries. 📊 𝗞𝗲𝘆 𝗙𝗶𝗻𝗱𝗶𝗻𝗴𝘀: 🔬 𝗥𝗲𝗮𝗳𝗳𝗶𝗿𝗺𝗶𝗻𝗴 𝗣𝗿𝗶𝗼𝗿𝗶𝘁𝘆 𝗗𝗶𝘀𝗲𝗮𝘀𝗲𝘀: The study highlights 𝗛𝗜𝗩, 𝗺𝗮𝗹𝗮𝗿𝗶𝗮, and 𝘁𝘂𝗯𝗲𝗿𝗰𝘂𝗹𝗼𝘀𝗶𝘀 as persistent global health threats, causing nearly 2.5 million deaths annually. 🚨 𝗘𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝗧𝗵𝗿𝗲𝗮𝘁𝘀: New priorities include Group A 𝙨𝙩𝙧𝙚𝙥𝙩𝙤𝙘𝙤𝙘𝙘𝙪𝙨 and 𝙆𝙡𝙚𝙗𝙨𝙞𝙚𝙡𝙡𝙖 𝙥𝙣𝙚𝙪𝙢𝙤𝙣𝙞𝙖𝙚, which pose growing risks due to antimicrobial resistance. 🌍 𝗘𝗾𝘂𝗶𝘁𝘆-𝗗𝗿𝗶𝘃𝗲𝗻 𝗥&𝗗: The WHO emphasizes that vaccine development must focus on the greatest health needs, ensuring that the most vulnerable populations benefit from life-saving innovations. 📊 𝗩𝗮𝗰𝗰𝗶𝗻𝗲 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗣𝗿𝗶𝗼𝗿𝗶𝘁𝗶𝗲𝘀: • 𝗜𝗺𝗺𝗲𝗱𝗶𝗮𝘁𝗲 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗡𝗲𝗲𝗱𝗲𝗱: Group A streptococcus, Hepatitis C, HIV, Klebsiella pneumoniae. • 𝗙𝘂𝗿𝘁𝗵𝗲𝗿 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗥𝗲𝗾𝘂𝗶𝗿𝗲𝗱: Cytomegalovirus, Influenza (broadly protective), Leishmania, Non-typhoidal Salmonella, Malaria, Shigella, Staphylococcus aureus. • 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗶𝗻𝗴 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗔𝗽𝗽𝗿𝗼𝘃𝗮𝗹: Dengue, Group B streptococcus, Extra-intestinal E. coli, Tuberculosis, RSV. 🌐 𝗦𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗜𝗺𝗺𝘂𝗻𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗔𝗴𝗲𝗻𝗱𝗮 𝟮𝟬𝟯𝟬: This study is crucial for guiding global vaccine R&D efforts, helping prioritize those diseases with the greatest burden and potential for impact in underserved communities. Follow Innovate Research for more such updates. World Health Organization #GlobalHealth #innovateresearch #CRO #clinicaltrials #vaccinetrials #VaccineResearch #PublicHealth #AntimicrobialResistance #WHO #VaccineDevelopment #ImmunizationAgenda2030 #HIV #Malaria #Tuberculosis #VaccineInnovation #HealthEquity #GlobalHealthPriorities #PandemicPreparedness #InfectiousDiseases #VaccineR&D #EndemicPathogens #HealthImpact #HealthResearch #WHOStudy

🚀 𝗜𝗖𝗠𝗥 𝗟𝗮𝘂𝗻𝗰𝗵𝗲𝘀 𝘁𝗵𝗲 "𝗙𝗶𝗿𝘀𝘁 𝗶𝗻 𝘁𝗵𝗲 𝗪𝗼𝗿𝗹𝗱 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲" – 𝗔 𝗖𝗮𝗹𝗹 𝗳𝗼𝗿 𝗚𝗿𝗼𝘂𝗻𝗱𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗕𝗶𝗼𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 🌍💡 The 𝗜𝗻𝗱𝗶𝗮𝗻 𝗖𝗼𝘂𝗻𝗰𝗶𝗹 𝗼𝗳 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 (𝗜𝗖𝗠𝗥) is set to accelerate India’s position as a global leader in healthcare innovation with the launch of the "𝗙𝗶𝗿𝘀𝘁 𝗶𝗻 𝘁𝗵𝗲 𝗪𝗼𝗿𝗹𝗱 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲". This bold initiative invites visionary scientists to push the boundaries of biomedical research and create revolutionary solutions for global health. 🔬 𝗪𝗵𝗮𝘁’𝘀 𝗮𝘁 𝘀𝘁𝗮𝗸𝗲? 𝗨𝗽 𝘁𝗼 𝗥𝘀. 𝟭 𝗖𝗿𝗼𝗿𝗲 for developing proof of concept (2 years). 𝗨𝗽 𝘁𝗼 𝗥𝘀. 𝟰 𝗖𝗿𝗼𝗿𝗲 for advancing concepts into working prototypes (4 years). 𝗨𝗽 𝘁𝗼 𝗥𝘀. 𝟴 𝗖𝗿𝗼𝗿𝗲 for transforming ideas into impactful final products. 👩🔬 𝗪𝗵𝗼 𝗰𝗮𝗻 𝗮𝗽𝗽𝗹𝘆? Scientists from 𝗴𝗼𝘃𝗲𝗿𝗻𝗺𝗲𝗻𝘁 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗰𝗼𝗹𝗹𝗲𝗴𝗲𝘀, 𝗜𝗖𝗠𝗥-𝗮𝗳𝗳𝗶𝗹𝗶𝗮𝘁𝗲𝗱 𝗶𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗶𝗼𝗻𝘀, 𝘂𝗻𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝗶𝗲𝘀, 𝗽𝗿𝗶𝘃𝗮𝘁𝗲 𝗶𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗶𝗼𝗻𝘀, 𝗡𝗚𝗢𝘀, 𝗮𝗻𝗱 𝗡𝗥𝗜𝘀/𝗢𝗖𝗜/𝗣𝗜𝗢𝘀 are invited to submit their proposals. ⏳ 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗱𝗲𝗮𝗱𝗹𝗶𝗻𝗲: 𝗡𝗼𝘃 𝟱 - 𝗗𝗲𝗰 𝟭𝟮, 𝟮𝟬𝟮𝟰 via the ICMR epms portal. 🌟 𝗪𝗵𝘆 𝗶𝘁 𝗺𝗮𝘁𝘁𝗲𝗿𝘀: This challenge offers 𝗵𝗶𝗴𝗵-𝘀𝘁𝗮𝗸𝗲𝘀 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 to fuel the next big breakthrough in healthcare. Whether it’s a game-changing vaccine, a new diagnostic tool, or a revolutionary treatment – if you’ve got an idea that could change the world, ICMR wants to hear from you. 🗣️ 𝗗𝗿. 𝗥𝗮𝗷𝗶𝘃 𝗕𝗮𝗵𝗹, 𝗗𝗚 𝗜𝗖𝗠𝗥: "𝘞𝘦 𝘢𝘳𝘦 𝘤𝘢𝘭𝘭𝘪𝘯𝘨 𝘰𝘯 𝘐𝘯𝘥𝘪𝘢'𝘴 𝘣𝘳𝘪𝘨𝘩𝘵𝘦𝘴𝘵 𝘮𝘪𝘯𝘥𝘴 𝘵𝘰 𝘣𝘳𝘪𝘯𝘨 𝘧𝘰𝘳𝘵𝘩 𝘪𝘥𝘦𝘢𝘴 𝘵𝘩𝘢𝘵 𝘸𝘪𝘭𝘭 𝘥𝘦𝘧𝘪𝘯𝘦 𝘵𝘩𝘦 𝘧𝘶𝘵𝘶𝘳𝘦 𝘰𝘧 𝘨𝘭𝘰𝘣𝘢𝘭 𝘩𝘦𝘢𝘭𝘵𝘩𝘤𝘢𝘳𝘦, 𝘫𝘶𝘴𝘵 𝘢𝘴 𝘐𝘯𝘥𝘪𝘢’𝘴 𝘴𝘶𝘤𝘤𝘦𝘴𝘴 𝘪𝘯 𝘊𝘩𝘢𝘯𝘥𝘳𝘢𝘺𝘢𝘢𝘯-3 𝘴𝘩𝘰𝘸𝘤𝘢𝘴𝘦𝘥 𝘰𝘶𝘳 𝘱𝘰𝘵𝘦𝘯𝘵𝘪𝘢𝘭 𝘰𝘯 𝘵𝘩𝘦 𝘸𝘰𝘳𝘭𝘥 𝘴𝘵𝘢𝘨𝘦." This is your chance to be part of something transformative. Let’s shape the future of healthcare, together. 🌍💥 Follow Innovate Research for more such informative updates. #ICMR #Innovation #innovateresearch #CRO #BiomedicalResearch #GlobalHealth #ResearchFunding #IndianInnovation #HealthcareBreakthrough #FirstInTheWorldChallenge #FutureOfHealthcare #MedicalInnovation #HealthcareRevolution #IndianResearchers #ScienceForGood #TechForHealth #BiomedicalEngineering #HealthTech #TransformingHealthcare #ResearchForChange #GlobalImpact #HealthInnovation #CuttingEdgeResearch

𝗛𝘂𝗶𝗱𝗮𝗚𝗲𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗥𝗲𝗰𝗲𝗶𝘃𝗲𝘀 𝗨.𝗦. 𝗙𝗗𝗔 𝗔𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗳𝗼𝗿 𝗖𝗥𝗜𝗦𝗣𝗥/𝗖𝗮𝘀𝟭𝟯 𝗥𝗡𝗔-𝗘𝗱𝗶𝘁𝗶𝗻𝗴 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗛𝗚𝟮𝟬𝟮 𝗳𝗼𝗿 𝗠𝗮𝗰𝘂𝗹𝗮𝗿 𝗗𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 HuidaGene Therapeutics has received FDA clearance for HG202, the first-ever 𝗖𝗥𝗜𝗦𝗣𝗥/𝗖𝗮𝘀𝟭𝟯 𝗥𝗡𝗔-𝗲𝗱𝗶𝘁𝗶𝗻𝗴 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗳𝗼𝗿 𝗻𝗲𝗼𝘃𝗮𝘀𝗰𝘂𝗹𝗮𝗿 𝗮𝗴𝗲-𝗿𝗲𝗹𝗮𝘁𝗲𝗱 𝗺𝗮𝗰𝘂𝗹𝗮𝗿 𝗱𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 (nAMD), a leading cause of vision loss in older adults. 🔬 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀: HG202 uses CRISPR/Cas13 technology to target VEGFA mRNA, involved in abnormal blood vessel growth in the eye. This RNA-editing approach could offer a better solution for patients who don’t respond to current anti-VEGF therapies, which have limited efficacy in some cases. 🧪 𝗕𝗥𝗜𝗚𝗛𝗧 𝗧𝗿𝗶𝗮𝗹: The BRIGHT trial is now underway to evaluate the safety and tolerability of HG202, with secondary endpoints focused on visual acuity improvements and reduced need for anti-VEGF injections. 💡 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻: HuidaGene's proprietary HG-PRECISE platform and high-fidelity Cas13Y system are driving the development of this novel RNA-editing therapy, with the potential to address a wide range of genetic diseases. 🌍 𝗜𝗺𝗽𝗮𝗰𝘁: HG202 could provide new hope for nAMD patients who have failed traditional treatments. HuidaGene is positioning itself as a leader in CRISPR-based RNA-editing therapies, with other promising clinical programs targeting genetic diseases like DMD and MECP2 duplication syndrome. Follow Innovate Research for more such interesting updates. #BiotechInnovation #innovateresearch #CRO #GenomeMedicine #CRISPRTherapy #RNAEditing #MacularDegeneration #VisionRestoration #GeneEditing #FDAApproval #MedicalResearch #GeneticTherapy #Biopharma #ClinicalTrials #HealthTech #PrecisionMedicine #CRISPRCas13 #AgeRelatedMacularDegeneration #VisionHealth #MedicalBreakthrough #BiotechNews #RNAtherapeutics #FutureOfMedicine #RegenerativeMedicine

📢𝐈𝐂𝐌𝐑 𝐢𝐧𝐯𝐢𝐭𝐞𝐬 𝐞𝐱𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐨𝐟 𝐢𝐧𝐭𝐞𝐫𝐞𝐬𝐭 𝐟𝐨𝐫 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐭𝐫𝐚𝐧𝐬𝐟𝐞𝐫 𝐭𝐨 𝐜𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥𝐢𝐳𝐞 𝐦𝐨𝐧𝐤𝐞𝐲𝐩𝐨𝐱 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐚𝐬𝐬𝐚𝐲 • The Indian Council of Medical Research (ICMR) has invited eligible organizations, companies, and manufacturers to submit an Expression of Interest (EoI) for commercializing a novel diagnostic technology developed by its National Institute of Virology (NIV). Key details are as follows: • Technology: A colorimetric isothermal (LAMP) assay for rapid detection of the monkeypox virus. • Submission Deadline: November 9, 2024. • Submission Requirements: Proposals should be in a sealed envelope labeled “EoI for Transfer of Technology for commercialization of a colorimetric isothermal (LAMP) assay for rapid detection of monkeypox virus” and sent to the ICMR headquarters, New Delhi. •Documentation: EoI document with qualifications, submission details, and evaluation criteria is available on the ICMR website [www.icmr.gov.in] Overview of Partnership Opportunity: • Objective: Licensing manufacturing rights for the rapid monkeypox detection assay. •Benefits to Chosen Company: •Rights to conduct additional R&D, manufacture, and commercialize the technology. •Option for joint development or exclusive/non-exclusive licensing to ensure broad distribution. •Technical guidance and support from NIV throughout the production process. ICMR’s Commitment: • IP Management: Adherence to the ICMR’s Intellectual Property Policy for regulatory and IP compliance. •Public Health Impact: This assay aligns with ICMR’s mission to support rapid, accessible diagnostics for effective outbreak response. • This innovation is a major advancement for viral diagnostics, and ICMR’s collaboration aims to make this tool widely available for public health. Keep track of the latest developments in clinical trials and regulatory compliance with expert-driven insights with Innovate Research #CRO #Clinicaltrials #Innovation #Pharmaceuticals #RegulatoryCompliance  #HealthTech #Biotechnology #PharmaceuticalDevelopment #DrugSynthesis #DrugDiscovery #PharmaInnovatio #ClinicalResearch #Biotech #Healthcare #SafetyEvaluation #MedTech #ICMR

📢 𝗧𝗿𝗶𝗮𝗹 𝘁𝗼 𝗮𝗱𝗱𝗿𝗲𝘀𝘀 𝗱𝗶𝘀𝗮𝗯𝗹𝗶𝗻𝗴 𝗰𝗼𝗴𝗻𝗶𝘁𝗶𝘃𝗲 𝗰𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻 𝗮𝗳𝗳𝗲𝗰𝘁𝗶𝗻𝗴 𝘀𝘁𝗿𝗼𝗸𝗲 𝘀𝘂𝗿𝘃𝗶𝘃𝗼𝗿𝘀 𝘁𝗼 𝗯𝗲𝗴𝗶𝗻 🗞𝗡𝗲𝘄 𝗧𝗿𝗶𝗮𝗹 𝗳𝗼𝗿 𝗣𝗼𝘀𝘁-𝗦𝘁𝗿𝗼𝗸𝗲 𝗖𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻: A major new trial is underway to test the efficacy of a new therapy, 𝗦𝗜𝗚𝗛𝗧, for spatial inattention, a disabling condition affecting many stroke survivors. 💰 𝗙𝘂𝗻𝗱𝗶𝗻𝗴: The £1.26 million funded by the EME Programme, a partnership between the NIHR and the MRC. 🏥 𝗦𝗽𝗮𝘁𝗶𝗮𝗹 𝗜𝗻𝗮𝘁𝘁𝗲𝗻𝘁𝗶𝗼𝗻: This condition arises from brain damage caused by stroke, leading to the inability to process information from one side of the body, even with good eyesight. 💉 𝗣𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝗧𝗵𝗲𝗿𝗮𝗽𝘆: The SIGHT therapy has shown promise in earlier small trials, offering hope for improved outcomes for stroke survivors with spatial inattention. The study will also explore why some people benefit more from therapy than others. To help identify who might benefit most, the trial will measure grasping, vision, cognition, stroke severity and brain structure and function. The successful application was written with the help of stroke survivors, family/carers, and clinicians.  Keep track of the latest developments in clinical trials and regulatory compliance with expert-driven insights with Innovate Research #CRO #Clinicaltrials #Innovation #Pharmaceuticals #RegulatoryCompliance #HealthTech #Biotechnology #PublicHealth #SME #PharmaceuticalDevelopment #DrugSynthesis #R&D #DrugDiscovery #PharmaInnovation #ClinicalResearch #Biotech #Healthcare #SafetyEvaluation #MedTech #Stroke #Vision

🌟✨ Wishing everyone a bright and joyful Diwali! May this festival of lights illuminate your path to success and fill your days with happiness and prosperity. Let's celebrate the spirit of togetherness and new beginnings.  Let's celebrate the spirit of Diwali - a festival that symbolizes hope, peace, and harmony. ✨🌟 Innovate Research #HappyDiwali #Joy #FestiveSeason #JoyfulDiwali #TraditionAndCulture #DiwaliWishes #DiwaliMubarak #CelebrateTogether #IlluminateYourLife

𝐆𝐥𝐢𝐦𝐩𝐬𝐞𝐬 𝐨𝐟 𝐃𝐢𝐰𝐚𝐥𝐢 𝐂𝐞𝐥𝐞𝐛𝐫𝐚𝐭𝐢𝐨𝐧 𝐚𝐭 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐞 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 ✨ Diwali brought us all together here at Innovate Research in the best way. We kicked off the celebration with a heartfelt Diwali Pooja, followed by a day full of laughter, delicious treats, and good company. Here's to the joy and warmth that festivals like these bring to our lives. Wishing everyone a wonderful and prosperous year ahead from our team. A heartfelt thank you to Dr. Devesh Kumar for the thoughtful Diwali gifts. Your kindness made our celebrations brighter and deeply appreciated by all. Happy Diwali 🎇🪔

May the divine light of Goddess Lakshmi illuminate your life with prosperity, happiness, and good health. On this auspicious occasion of Dhanteras, let's embrace the spirit of giving and sharing, and may your home be filled with joy and abundance.✨ 💥 Wishing a very Happy Dhanteras from Team Innovate Research 💥 #धनतेरस #शुभ_धनतेरस #धन_तेरस #धन_वृद्धि #लक्ष्मी_पूजा